2023 10 v.16 865-885
中国老年骨质疏松症诊疗指南（2023）
基金项目(Foundation):
国家重点研发计划（2020YFC2008900）
邮箱(Email):
DOI:
中文作者单位:
解放军总医院第八医学中心老年医学科;哈尔滨医科大学附属第二医院骨科;苏州大学附属第一医院骨科;解放军总医院第二医学中心内分泌科;青岛大学附属医院内分泌科;首都医科大学附属北京积水潭医院放射科;青岛大学附属医院骨科;上海市伤骨科研究所上海市骨与关节病损重点实验室;解放军总医院第二医学中心老年医学科;解放军总医院第四医学中心骨科医学部;香港中文大学矫形外科及创伤学系;中国医学科学院北京协和医学院北京协和医院骨科;
摘要(Abstract):
中国老年学和老年医学学会骨质疏松分会联合中国医疗保健国际交流促进会骨质疏松病学分会、中国康复医学会骨质疏松预防与康复专业委员会和老年常见临床问题防控技术综合示范研究课题组，根据国内外循证医学指南制订标准化方法与步骤，组建多学科指南制定专家工作组，基于近5年发表的国内外老年骨质疏松症相关研究证据，围绕《中国老年骨质疏松症诊疗指南（2018）》梳理的临床问题，结合新调研确定的临床问题，采用GRADE方法对系统评价的证据质量和推荐强度分级，对其进行更新，旨在更好地规范和指导我国老年骨质疏松症的临床诊治工作，为患者提供安全、高效的医疗服务。
关键词(KeyWords):
老年骨质疏松症;;循证医学;;系统评价;;临床指南
| 10,638 | 116 | 497 |
| 下载次数 | 被引频次 | 阅读次数 |
参考文献
[1]Bijlsma AY,Meskers CG,Westendorp RG,et al.Chronology of age-related disease definitions:osteoporosis and sarcopenia[J].Ageing Res Rev,2012,11(2):320-324.
[2]NIH Consensus Development Panel on Osteoporosis Prevention,Diagnosis,and Therapy,March 7-29,2000:highlights of the conference[J].South Med J,2001,94(6):569-573.
[3]Seriolo B,Paolino S,Casabella A,et al.Osteoporosis in the elderly[J].Aging Clin Exp Res,2013,25 Suppl 1:S27-S 29.
[4]陈蕃.21世纪老龄问题研究[M].北京:宇航出版社,1993.
[5]中华人民共和国国家统计局.中国统计年鉴[M].北京:中国统计出版社,2022.
[6]中国疾病预防控制中心,中华医学会骨质疏松和骨矿盐疾病分会.中国骨质疏松症流行病学调查报告(2018)[M].北京:人民卫生出版社,2021.
[7]Wang L,Yu W,Yin X,et al.Prevalence of osteoporosis and fracture in China:the China osteoporosis prevalence study[J].JAMA Netw Open,2021,4(8):e2121106.
[8]Si L,Winzenberg TM,Jiang Q,et al.Projection of osteoporosis-related fractures and costs in China:2010-2050[J].Osteoporos Int,2015,26(7):1929-1937.
[9]Osnes EK,Lofthus CM,Meyer HE,et al.Consequences of hip fracture on activities of daily life and residential needs[J].Osteoporos Int,2004,15(7):567-574.
[10]Wang O,Hu Y,Gong S,et al.A survey of outcomes and management of patients post fragility fractures in China[J].Osteoporos Int,2015,26(11):2631-2640.
[11]Shapiro J,Bernica J,Hernaez R.Risk of bias analysis of systematic reviews of probiotics for treatment of irritable bowel syndrome[J].Clin Gastroenterol Hepatol,2019,17(4):784-785.
[12]Bergman J,Nordstr?m A,Nordstr?m P.Bisphosphonate use after clinical fracture and risk of new fracture[J].Osteoporos Int,2018,29(4):937-945.
[13]Hopkins SJ,Toms AD,Brown M,et al.Disuse osteopenia following leg fracture in postmenopausal women:implications for hip fracture risk and fracture liaison services[J].Radiography (Lond),2018,24(2):151-158.
[14]Duque G,Troen BR.Understanding the mechanisms of senile osteoporosis:new facts for a major geriatric syndrome[J].J Am Geriatr Soc,2008,56(5):935-941.
[15]丁超,孙强.老年性骨质疏松症相关问题研究进展[J].中国骨质疏松杂志,2016,22(3):372-375.
[16]王洪复.老年性骨质疏松症病理机制与防治原则[J].中华保健医学杂志,2010,12(1):1-4.
[17]王鸥,邢小平.老年性骨质疏松症发病机制及药物治疗进展[J].中国实用内科杂志,2011,31(8):584-586.
[18]Starup-Linde J,Vestergaard P.Management of endocrine disease:Diabetes and osteoporosis:cause for concern?[J].Eur J Endocrinol,2015,173(3):R93-R99.
[19]Feng J,Liu S,Ma S,et al.Protective effects of resveratrol on postmenopausal osteoporosis:regulation of SIRT1-NF-κB signaling pathway[J].Acta Biochim Biophys Sin(Shanghai),2014,46(12):1024-1033.
[20]Orimo H,Nakamura T,Hosoi T,et al.Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary[J].Arch Osteoporos,2012,7(1):3-20.
[21]Schulman RC,Weiss AJ,Mechanick JI.Nutrition,bone,and aging:an integrative physiology approach[J].Curr Osteoporos Rep,2011,9(4):184-195.
[22]Liu X,Wan M.A tale of the good and bad:cell senescence in bone homeostasis and disease[J].Int Rev Cell Mol Biol,2019,346:97-128.
[23]Xiao YZ,Yang M,Xiao Y,et al.Reducing hypothalamic stem cell senescence protects against aging-associated physiological decline[J].Cell Metab,2020,31(3):534-548.e5.
[24]Farr JN,Rowsey JL,Eckhardt BA,et al.Independent roles of estrogen deficiency and cellular senescence in the pathogenesis of osteoporosis:evidence in young adult mice and older humans[J].J Bone Miner Res,2019,34(8):1407-1418.
[25]Farr JN,Xu M,Weivoda MM,et al.Targeting cellular senescence prevents age-related bone loss in mice[J].Nat Med,2017,23(9):1072-1079.
[26]Farr JN,Khosla S.Cellular senescence in bone[J].Bone,2019,121:121-133.
[27]Farr JN,Fraser DG,Wang H,et al.Identification of senescent cells in the bone microenvironment[J].J Bone Miner Res,2016,31:1920-1929．
[28]Liu F,Yuan Y,Bai L,et al.LRRc17 controls BMSC senescence via mitophagy and inhibits the therapeutic effect of BMSCs on ovariectomy-induced bone loss[J].Redox Biol,2021,43:101963.
[29]Li CJ,Xiao Y,Sun YC,et al.Senescent immune cells release grancalcin to promote skeletal aging[J].Cell Metab,2021,33:1957-1973.e6.
[30]Locantore P,Del Gatto V,Gelli S,et al.The interplay between immune system and microbiota in osteoporosis[J].Mediators Inflamm,2020:3686749.
[31]Sato K,Suematsu A,Okamoto K,et al.Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction[J].J Exp Med,2006,203:2673-2682.
[32]Lucas S,Omata Y,Hofmann J,et al.Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss[J].Nat Commun,2018,9:55.
[33]Tyagi AM,Yu M,Darby TM,et al.The microbial metabolite butyrate stimulates bone formation via T regulatory cellmediated regulation of WNT10B expression[J].Immunity,2018,49:1116-1131.e7.
[34]Xie H,Cui Z,Wang L,et al.PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis[J].Nat Med,2014,20:1270-1278.
[35]Zhou YM,Yang YY,Jing YX,et al.BMP9 reduces bone loss in ovariectomized mice by dual regulation of bone remodeling[J].J Bone Miner Res,2020,35:978-993.
[36]Esen E,Lee SY,Wice BM,et al.PTH promotes bone anabolism by stimulating aerobic glycolysis via IGF signaling[J].J Bone Miner Res,2015,30:1959-1968.
[37]Esen E,Chen J,Karner CM,et al.WNT-LRP5 signaling induces Warburg effect through m TORC2 activation during osteoblast differentiation[J].Cell Metab,2013,17:745-755.
[38]Yang YY,Zhou YM,Xu JZ,et al.Lgr4 promotes aerobic glycolysis and differentiation in osteoblasts via the canonical Wnt/β-catenin pathway[J].J Bone Miner Res,2021,36:1605-1620.
[39]Li GF,Pan YZ,Sirois P,et al.Iron homeostasis in osteoporosis and its clinical implications[J].Osteoporos Int,2012,23:2403-2408.
[40]李光飞,张辉,王爱飞,等.铁蓄积通过干扰Wnt信号通路导致骨质疏松[J].中华内分泌代谢杂志,2019,35:1061-1064.
[41]Yuan Y,Fang Y,Zhu L,et al.Deterioration of hematopoietic autophagy is linked to osteoporosis[J].Aging Cell,2020,19:e13114.
[42]张萌萌,张秀珍,邓伟民,等.骨代谢生化指标临床应用专家共识[J].中国骨质疏松杂志,2020,26(6):781-796.
[43]Vasikaran S,Eastell R,Bruyère O,et al.Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment:a need for international reference standards[J].Osteoporos Int,2011,22(2):391-420.
[44]Bauer D,Krege J,Lane N,et al.National bone health alliance bone turnover marker project:current practices and the need for US harmonization,standardization,and common reference ranges[J].Osteoporos Int,2012,23(10):2425-2433.
[45]WPark SY,Ahn SH,Yoo JI,et al.Position statement on the use of bone turnover markers for osteoporosis treatment[J].J Bone Metab,2019,26(4):213-224.
[46]Eastell R,Pigott T,Gossiel F,et al.Diagnosis of endocrine disease:bone turnover markers:are they clinically useful?[J].Eur J Endocrinol,2018,178(1):R19-R31.
[47]Naylor KE,Jacques RM,Paggiosi M,et al.Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis:the TRIO study[J].Osteoporos Int,2016,27(1):21-31.
[48]Eastell R,Krege JH,Chen P,et al.Development of an algorithm for using PINP to monitor treatment of patients with teriparatide[J].Curr Med Res Opin,2006,22(1):61-66.
[49]Genant HK,Cann CE,Ettinger B,et al.Quantitative computed tomography of vertebral spongiosa:a sensitive method for detecting early bone loss after oophorectomy[J].Ann Intern Med,1982,97(5):699-705.
[50]马远征,王以朋,刘强,等.中国老年骨质疏松症诊疗指南(2018)[J].中国骨质疏松杂志,2018,24(12):1541-1567.
[51]《中国定量CT(QCT)骨质疏松症诊断指南》工作组,程晓光,王亮,等.中国定量CT(QCT)骨质疏松症诊断指南(2018)[J].中国骨质疏松杂志,2019,25(6):733-737.
[52]Mann C,Ziegeler K,Mews J,et al.Bone mineral density assessment using iterative reconstruction compared with quantitative computed tomography as the standard of reference[J].Sci Rep,2018,8(1):15095.
[53]Adams AL,Fischer H,Kopperdahl DL,et al.Osteoporosis and hip fracture risk from routine computed tomography scans:the fracture,osteoporosis,and CT utilization study(FOCUS)[J].J Bone Miner Res,2018,33(7):1291-1301.
[54]Engelke K,Adams JE,Armbrecht G,et al.Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults:the 2007 ISCD official positions[J].J Clin Densitom,2008,11(1):123-162.
[55]American College of Radiology.ACR-SPR-SSR practice parameter for the performance of musculoskeletal quantitative computed tomography (QCT) bone mineral density[EB/OL].[2022-08-05].https://www.acr.org/-/media/ACR/Files/Practice-Parameters/QCT.pdf.
[56]李凯,陈捷,赵林芬,等.中国人群定量CT(QCT)脊柱骨密度正常参考值的建立和骨质疏松症QCT诊断标准的验证[J].中国骨质疏松杂志,2019,25(9):12571262,1272.
[57]Cheng X,Zhao K,Zha X,et al.Opportunistic screening using lowdose CT and the prevalence of osteoporosis in China:a nationwide,multicenter study[J].J Bone Miner Res,2021,36(3):427435.
[58]Yuan Y,Zhang P,Tian W,et al.Application of bone turnover markers and DXA and QCT in an elderly Chinese male population[J].Ann Palliat Med,2021,10(6):6351-6358.
[59]Xu XM,Li N,Li K,et al.Discordance in diagnosis of osteoporosis by quantitative computed tomography and dualenergy X-ray absorptiometry in Chinese elderly men[J].JOrthop Translat,2018,18:59-64.
[60]中国营养学会.中国居民膳食指南(2022)[M].北京:人民卫生出版社,2022.
[61]中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2022)[J].中华骨质疏松和骨矿盐疾病杂志,2022,15(6):573-611.
[62]Shi Y,Zhan Y,Chen Y,et al.Effects of dairy products on bone mineral density in healthy postmenopausal women:a systematic review and meta-analysis of randomized controlled trials[J].Arch Osteoporos,2020,15(1):48.
[63]Bristow SM,Bolland MJ,Gamble GD,et al.Dietary calcium intake and change in bone mineral density in older adults:a systematic review of longitudinal cohort studies[J].Eur J Clin Nutr,2022,76(2):196-205.
[64]中国营养学会骨营养与健康分会,中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症患者的营养和运动管理专家共识[J].中华内分泌代谢杂志,2020,36(8):643-653.
[65]Sakhaee K,Bhuket T,Adams-Huet B,et al.Meta-analysis of calcium bioavailability:a comparison of calcium citrate with calcium carbonate[J].Am J Ther,1999,6(6):313-322.
[66]邢小平,母义明.临床路径治疗药物释义·内分泌病与代谢病分册[M].北京:中国协和医科大学出版社,2018.
[67]王琴芳,赵朝伟,杨俊卿.枸橼酸钙治疗骨质疏松症的作用特点[J].中国药业,2003,12(2):77-78.
[68]Min CY,Yoo DM,Choi HG.Associations between physical activity,sunshine duration and osteoporosis according to obesity and other lifestyle factors:a nested case-control study[J].Int J Environ Res Public Health,2021,18(9):4437.
[69]Liu H,Wang G,Wu T,et al.Efficacy and safety of eldecalcitol for osteoporosis:a meta-analysis of randomized controlled trials[J].Front Endocrinol (Lausanne),2022,13:854439.
[70]Xu Z,Fan C,Zhao X,et al.Treatment of osteoporosis with eldecalcitol,a new vitamin D analog:a comprehensive review and meta-analysis of randomized clinical trials[J].Drug Des Devel Ther,2016,10:509-517.
[71]Assantachai P,Chatthanawaree W,Thamlikitkul V,et al.Strategy to prevent falls in the Thai elderly:a controlled study integrated health research program for the Thai elderly[J].J Med Assoc Thai,2002,85(2):215-222.
[72]Minneci C,Mello AM,Mossello E,et al.Comparative study of four physical performance measures as predictors of death,incident disability,and falls in unselected older persons:the insufficienza Cardiaca negli Anziani Residenti a Dicomano Study[J].J Am Geriatr Soc,2015,63(1):136-141.
[73]Peng K,Tian M,Andersen M,et al.Incidence,risk factors and economic burden of fall-related injuries in older Chinese people:a systematic review[J].Inj Prev,2019,25(1):4-12.
[74]Gillespie LD,Robertson MC,Gillespie WJ,et al.Interventions for preventing falls in older people living in the community[J].Cochrane Database Syst Rev,2012,2012(9):CD007146.
[75]Gregson CL,Armstrong DJ,Bowden J,et al.UK clinical guideline for the prevention and treatment of osteoporosis[J].Arch Osteoporos,2022,17(1):58.
[76]Chaplin S.SIGN on managing osteoporosis and fragility fracture prevention[J].Prescriber,2021,32(2):29-32.
[77]Sinaki M.Exercise for patients with osteoporosis:management of vertebral compression fractures and trunk strengthening for fall prevention[J].PM R,2012,4(11):882-888.
[78]Wang Q,Jiang X,Shen Y,et al.Effectiveness of exercise intervention on fall-related fractures in older adults:a systematic review and meta-analysis of randomized controlled trials[J].BMC Geriatr,2020,20(1):322.
[79]Zhao R,Bu W,Chen X.The efficacy and safety of exercise for prevention of fall-related injuries in older people with different health conditions,and differing intervention protocols:a meta-analysis of randomized controlled trials[J].BMC Geriatr,2019,19(1):341.
[80]N?rgaard JE,Jorgensen MG,Ryg J,et al.Effects of gait adaptability training on falls and fall-related fractures in older adults:a systematic review and meta-analysis[J].Age Ageing,2021,50(6):1914-1924.
[81]El-Khoury F,Cassou B,Charles MA,et al.The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults:systematic review and meta-analysis of randomised controlled trials[J].BMJ,2013,347:f6234.
[82]Ong MF,Soh KL,Saimon R,et al.Fall prevention education to reduce fall risk among communitydwelling older persons:a systematic review[J].J Nurs Manag,2021,29(8):2674-2688.
[83]Scott V,Votova K,Scanlan A,et al.Multifactorial and functional mobility assessment tools for fall risk among older adults in community,home-support,long-term and acute care settings[J].Age Ageing,2007,36(2):130-139.
[84]Lachance CC,Jurkowski MP,Dymarz AC,et al.Compliant flooring to prevent fall-related injuries in older adults:a scoping review of biomechanical efficacy,clinical effectiveness,cost-effectiveness,and workplace safety[J].PLo SOne,2017,12(2):e0171652.
[85]Dautzenberg L,Beglinger S,Tsokani S,et al.Interventions for preventing falls and fallrelated fractures in communitydwelling older adults:a systematic review and network meta-analysis[J].J Am Geriatr Soc,2021,69(10):2973-2984.
[86]Hart LA,Phelan EA,Yi JY,et al.Use of fall risk-increasing drugs around a fall-related injury in older adults:a systematic review[J].J Am Geriatr Soc,2020,68(6):1334-1343.
[87]Kohrt WM,Bloomfield SA,Little KD,et al.Physical activity and bone health[J].Med Sci Sports Exerc,2004,36(11):1985-1996.
[88]Kistler-Fischbacher M,Weeks BK,Beck BR.The effect of exercise intensity on bone in postmenopausal women (part2):a meta-analysis[J].Bone,2021,143:115697.
[89]Zhao R,Zhang M,Zhang Q.The effectiveness of combined exercise interventions for preventing postmenopausal bone loss:a systematic review and meta-analysis[J].J Orthop Sports Phys Ther,2017,47(4):241-251.
[90]Babatunde OO,Bourton AL,Hind,et al.Exercise interventions for preventing and treating low bone mass in the forearm:a systematic review and meta-analysis[J].Arch Phys Med Rehabil,2020,101(3):487-511.
[91]Zhao R,Bu W,Chen X.The efficacy and safety of exercise for prevention of fall-related injuries in older people with different health conditions,and differing intervention protocols:a meta-analysis of randomized controlled trials[J].BMC Geriatr,2019,19(1):341.
[92]Pinheiro MB,Oliveira J,Bauman A,et al.Evidence on physical activity and osteoporosis prevention for people aged 65+years:a systematic review to inform the WHOguidelines on physical activity and sedentary behaviour[J].Int J Behav Nutr Phys Act,2020,17(1):150.
[93]Ponzano M,Rodrigues IB,Hosseini Z,et al.Progressive resistance training for improving health-related outcomes in people at risk of fracture:a systematic review and metaanalysis of randomized controlled trials[J].Phys Ther,2021,101(2):pzaa221.
[94]Kemmler W,Shojaa M,Kohl M,et al.Effects of different types of exercise on bone mineral density in postmenopausal women:a systematic review and meta-analysis[J].Calcif Tissue Int,2020,107(5):409-439.
[95]Piercy KL,Troiano RP,Ballard RM,et al.The physical activity guidelines for Americans[J].JAMA,2018,320(19):2020-2028.
[96]Benedetti MG,Furlini G,Zati A,et al.The effectiveness of physical exercise on bone density in osteoporotic patients[J].Biomed Res Int,2018,2018:4840531.
[97]Castellano D,Sepulveda JM,García-Escobar I,et al.The role of RANK-ligand inhibition in cancer:the story of denosumab[J].Oncologist,2011,16(2):136-145.
[98]中华医学会骨质疏松和骨矿盐疾病分会.地舒单抗在骨质疏松症临床合理用药的中国专家建议[J].中华骨质疏松和骨矿盐疾病杂志,2020,13(6):499-508.
[99]Chen Y,Zhu J,Zhou Y,et al.Efficacy and safety of denosumab in osteoporosis or low bone mineral density postmenopausal women[J].Front Pharmacol,2021,12:588095.
[100]Lyu H,Jundi B,Xu C,et al.Comparison of denosumab and bisphosphonates in patients with osteoporosis:a metaanalysis of randomized controlled trials[J].J Clin Endocrinol Metab,2019,104(5):1753-1765.
[101]Wu J,Zhang Q,Yan G,et al.Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis:a meta-analysis[J].J Orthop Surg Res,2018,13(1):194.
[102]Mandema JW,Zheng J,Libanati C,et al.Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis:a doseresponse-based meta-analysis[J].J Clin Endocrinol Metab,2014,99(10):3746-3755.
[103]Li L,Gong M,Bao D,et al.Denosumab and romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis:a reanalysis of the meta-analysis[J].Bone,2020,134:115270.
[104]Bone HG,Wagman RB,Brandi ML,et al.10 years of denosumab treatment in postmenopausal women with osteoporosis:results from the phase 3 randomised FREEDOMtrial and open-label extension[J].Lancet Diabetes Endocrinol,2017,5(7):513-523.
[105]Gopaul A,Kanagalingam T,Thain J,et al.Denosumab in chronic kidney disease:a narrative review of treatment efficacy and safety[J].Arch Osteoporos,2021,16(1):116.
[106]Chen CH,Lo WC,Hu PJ,et al.Efficacy of osteoporosis medications for patients with chronic kidney disease:an updated systematic review and network meta-analysis[J].Front Pharmacol,2022,13:822178.
[107]Cummings SR,Ferrari S,Eastell R,et al.Vertebral fractures after discontinuation of denosumab:a post hoc analysis of the randomized placebocontrolled FREEDOM trial and its extension[J].J Bone Miner Res,2018,33(2):190-198.
[108]Tsourdi E,Langdahl B,Cohen-Solal M,et al.Discontinuation of Denosumab therapy for osteoporosis:a systematic review and position statement by ECTS[J].Bone,2017,105:11-17.
[109]Wan Y,Zeng F,Tan H,et al.Cost-effectiveness analyses of denosumab for osteoporosis:a systematic review[J].Osteoporos Int,2022,33(5):979-1015.
[110]Mc Clung MR,Grauer A,Boonen S,et al.Romosozumab in postmenopausal women with low bone mineral density[J].N Engl J Med,2014,370(5):412-420.
[111]李宁,李新萍,杨明辉,等.老年髋部骨折的骨质疏松症诊疗专家共识[J].中华骨与关节外科杂志,2021,14(8):657-663.
[112]Eastell R,Rosen CJ,Black DM,et al.Pharmacological management of osteoporosis in postmenopausal women:an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab,2019,104(5):1595-1622.
[113]Camacho PM,Petak SM,Binkley N,et al.American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update[J].Endocr Pract,2020,26(Suppl 1):1-46.
[114]Kanis JA,Harvey NC,Mc Closkey E,et al.Algorithm for the management of patients at low,high and very high risk of osteoporotic fractures[J].Osteoporos Int,2020,31(1):1-12.
[115]Singh S,Dutta S,Khasbage S,et al.A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis[J].Osteoporos Int,2022,33(1):1-12.
[116]Shen J,Ke Z,Dong S,et al.Pharmacological therapies for osteoporosis:a Bayesian network meta-analysis[J].Med Sci Monit,2022,28:e935491.
[117]Cosman F,Crittenden DB,Adachi JD,et al.Romosozumab treatment in postmenopausal women with osteoporosis[J].N Engl J Med,2016,375(16):1532-1543.
[118]Saag KG,Petersen J,Brandi ML,et al.Romosozumab or alendronate for fracture prevention in women with osteoporosis[J].N Engl J Med,2017,377(15):1417-1427.
[119]Lv F,Cai X,Yang W,et al.Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis:systematic review and meta-analysis[J].Bone,2020,130:115-121.
[120]Body JJ,Bergmann P,Boonen S,et al.Non-pharmacological management of osteoporosis:a consensus of the Belgian Bone Club[J].Osteoporos Int,2011,22(11):2769-2788.
[121]Rondanelli M,Faliva MA,Barrile GC,et al.Nutrition,physical activity,and diet
[2]NIH Consensus Development Panel on Osteoporosis Prevention,Diagnosis,and Therapy,March 7-29,2000:highlights of the conference[J].South Med J,2001,94(6):569-573.
[3]Seriolo B,Paolino S,Casabella A,et al.Osteoporosis in the elderly[J].Aging Clin Exp Res,2013,25 Suppl 1:S27-S 29.
[4]陈蕃.21世纪老龄问题研究[M].北京:宇航出版社,1993.
[5]中华人民共和国国家统计局.中国统计年鉴[M].北京:中国统计出版社,2022.
[6]中国疾病预防控制中心,中华医学会骨质疏松和骨矿盐疾病分会.中国骨质疏松症流行病学调查报告(2018)[M].北京:人民卫生出版社,2021.
[7]Wang L,Yu W,Yin X,et al.Prevalence of osteoporosis and fracture in China:the China osteoporosis prevalence study[J].JAMA Netw Open,2021,4(8):e2121106.
[8]Si L,Winzenberg TM,Jiang Q,et al.Projection of osteoporosis-related fractures and costs in China:2010-2050[J].Osteoporos Int,2015,26(7):1929-1937.
[9]Osnes EK,Lofthus CM,Meyer HE,et al.Consequences of hip fracture on activities of daily life and residential needs[J].Osteoporos Int,2004,15(7):567-574.
[10]Wang O,Hu Y,Gong S,et al.A survey of outcomes and management of patients post fragility fractures in China[J].Osteoporos Int,2015,26(11):2631-2640.
[11]Shapiro J,Bernica J,Hernaez R.Risk of bias analysis of systematic reviews of probiotics for treatment of irritable bowel syndrome[J].Clin Gastroenterol Hepatol,2019,17(4):784-785.
[12]Bergman J,Nordstr?m A,Nordstr?m P.Bisphosphonate use after clinical fracture and risk of new fracture[J].Osteoporos Int,2018,29(4):937-945.
[13]Hopkins SJ,Toms AD,Brown M,et al.Disuse osteopenia following leg fracture in postmenopausal women:implications for hip fracture risk and fracture liaison services[J].Radiography (Lond),2018,24(2):151-158.
[14]Duque G,Troen BR.Understanding the mechanisms of senile osteoporosis:new facts for a major geriatric syndrome[J].J Am Geriatr Soc,2008,56(5):935-941.
[15]丁超,孙强.老年性骨质疏松症相关问题研究进展[J].中国骨质疏松杂志,2016,22(3):372-375.
[16]王洪复.老年性骨质疏松症病理机制与防治原则[J].中华保健医学杂志,2010,12(1):1-4.
[17]王鸥,邢小平.老年性骨质疏松症发病机制及药物治疗进展[J].中国实用内科杂志,2011,31(8):584-586.
[18]Starup-Linde J,Vestergaard P.Management of endocrine disease:Diabetes and osteoporosis:cause for concern?[J].Eur J Endocrinol,2015,173(3):R93-R99.
[19]Feng J,Liu S,Ma S,et al.Protective effects of resveratrol on postmenopausal osteoporosis:regulation of SIRT1-NF-κB signaling pathway[J].Acta Biochim Biophys Sin(Shanghai),2014,46(12):1024-1033.
[20]Orimo H,Nakamura T,Hosoi T,et al.Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary[J].Arch Osteoporos,2012,7(1):3-20.
[21]Schulman RC,Weiss AJ,Mechanick JI.Nutrition,bone,and aging:an integrative physiology approach[J].Curr Osteoporos Rep,2011,9(4):184-195.
[22]Liu X,Wan M.A tale of the good and bad:cell senescence in bone homeostasis and disease[J].Int Rev Cell Mol Biol,2019,346:97-128.
[23]Xiao YZ,Yang M,Xiao Y,et al.Reducing hypothalamic stem cell senescence protects against aging-associated physiological decline[J].Cell Metab,2020,31(3):534-548.e5.
[24]Farr JN,Rowsey JL,Eckhardt BA,et al.Independent roles of estrogen deficiency and cellular senescence in the pathogenesis of osteoporosis:evidence in young adult mice and older humans[J].J Bone Miner Res,2019,34(8):1407-1418.
[25]Farr JN,Xu M,Weivoda MM,et al.Targeting cellular senescence prevents age-related bone loss in mice[J].Nat Med,2017,23(9):1072-1079.
[26]Farr JN,Khosla S.Cellular senescence in bone[J].Bone,2019,121:121-133.
[27]Farr JN,Fraser DG,Wang H,et al.Identification of senescent cells in the bone microenvironment[J].J Bone Miner Res,2016,31:1920-1929．
[28]Liu F,Yuan Y,Bai L,et al.LRRc17 controls BMSC senescence via mitophagy and inhibits the therapeutic effect of BMSCs on ovariectomy-induced bone loss[J].Redox Biol,2021,43:101963.
[29]Li CJ,Xiao Y,Sun YC,et al.Senescent immune cells release grancalcin to promote skeletal aging[J].Cell Metab,2021,33:1957-1973.e6.
[30]Locantore P,Del Gatto V,Gelli S,et al.The interplay between immune system and microbiota in osteoporosis[J].Mediators Inflamm,2020:3686749.
[31]Sato K,Suematsu A,Okamoto K,et al.Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction[J].J Exp Med,2006,203:2673-2682.
[32]Lucas S,Omata Y,Hofmann J,et al.Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss[J].Nat Commun,2018,9:55.
[33]Tyagi AM,Yu M,Darby TM,et al.The microbial metabolite butyrate stimulates bone formation via T regulatory cellmediated regulation of WNT10B expression[J].Immunity,2018,49:1116-1131.e7.
[34]Xie H,Cui Z,Wang L,et al.PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis[J].Nat Med,2014,20:1270-1278.
[35]Zhou YM,Yang YY,Jing YX,et al.BMP9 reduces bone loss in ovariectomized mice by dual regulation of bone remodeling[J].J Bone Miner Res,2020,35:978-993.
[36]Esen E,Lee SY,Wice BM,et al.PTH promotes bone anabolism by stimulating aerobic glycolysis via IGF signaling[J].J Bone Miner Res,2015,30:1959-1968.
[37]Esen E,Chen J,Karner CM,et al.WNT-LRP5 signaling induces Warburg effect through m TORC2 activation during osteoblast differentiation[J].Cell Metab,2013,17:745-755.
[38]Yang YY,Zhou YM,Xu JZ,et al.Lgr4 promotes aerobic glycolysis and differentiation in osteoblasts via the canonical Wnt/β-catenin pathway[J].J Bone Miner Res,2021,36:1605-1620.
[39]Li GF,Pan YZ,Sirois P,et al.Iron homeostasis in osteoporosis and its clinical implications[J].Osteoporos Int,2012,23:2403-2408.
[40]李光飞,张辉,王爱飞,等.铁蓄积通过干扰Wnt信号通路导致骨质疏松[J].中华内分泌代谢杂志,2019,35:1061-1064.
[41]Yuan Y,Fang Y,Zhu L,et al.Deterioration of hematopoietic autophagy is linked to osteoporosis[J].Aging Cell,2020,19:e13114.
[42]张萌萌,张秀珍,邓伟民,等.骨代谢生化指标临床应用专家共识[J].中国骨质疏松杂志,2020,26(6):781-796.
[43]Vasikaran S,Eastell R,Bruyère O,et al.Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment:a need for international reference standards[J].Osteoporos Int,2011,22(2):391-420.
[44]Bauer D,Krege J,Lane N,et al.National bone health alliance bone turnover marker project:current practices and the need for US harmonization,standardization,and common reference ranges[J].Osteoporos Int,2012,23(10):2425-2433.
[45]WPark SY,Ahn SH,Yoo JI,et al.Position statement on the use of bone turnover markers for osteoporosis treatment[J].J Bone Metab,2019,26(4):213-224.
[46]Eastell R,Pigott T,Gossiel F,et al.Diagnosis of endocrine disease:bone turnover markers:are they clinically useful?[J].Eur J Endocrinol,2018,178(1):R19-R31.
[47]Naylor KE,Jacques RM,Paggiosi M,et al.Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis:the TRIO study[J].Osteoporos Int,2016,27(1):21-31.
[48]Eastell R,Krege JH,Chen P,et al.Development of an algorithm for using PINP to monitor treatment of patients with teriparatide[J].Curr Med Res Opin,2006,22(1):61-66.
[49]Genant HK,Cann CE,Ettinger B,et al.Quantitative computed tomography of vertebral spongiosa:a sensitive method for detecting early bone loss after oophorectomy[J].Ann Intern Med,1982,97(5):699-705.
[50]马远征,王以朋,刘强,等.中国老年骨质疏松症诊疗指南(2018)[J].中国骨质疏松杂志,2018,24(12):1541-1567.
[51]《中国定量CT(QCT)骨质疏松症诊断指南》工作组,程晓光,王亮,等.中国定量CT(QCT)骨质疏松症诊断指南(2018)[J].中国骨质疏松杂志,2019,25(6):733-737.
[52]Mann C,Ziegeler K,Mews J,et al.Bone mineral density assessment using iterative reconstruction compared with quantitative computed tomography as the standard of reference[J].Sci Rep,2018,8(1):15095.
[53]Adams AL,Fischer H,Kopperdahl DL,et al.Osteoporosis and hip fracture risk from routine computed tomography scans:the fracture,osteoporosis,and CT utilization study(FOCUS)[J].J Bone Miner Res,2018,33(7):1291-1301.
[54]Engelke K,Adams JE,Armbrecht G,et al.Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults:the 2007 ISCD official positions[J].J Clin Densitom,2008,11(1):123-162.
[55]American College of Radiology.ACR-SPR-SSR practice parameter for the performance of musculoskeletal quantitative computed tomography (QCT) bone mineral density[EB/OL].[2022-08-05].https://www.acr.org/-/media/ACR/Files/Practice-Parameters/QCT.pdf.
[56]李凯,陈捷,赵林芬,等.中国人群定量CT(QCT)脊柱骨密度正常参考值的建立和骨质疏松症QCT诊断标准的验证[J].中国骨质疏松杂志,2019,25(9):12571262,1272.
[57]Cheng X,Zhao K,Zha X,et al.Opportunistic screening using lowdose CT and the prevalence of osteoporosis in China:a nationwide,multicenter study[J].J Bone Miner Res,2021,36(3):427435.
[58]Yuan Y,Zhang P,Tian W,et al.Application of bone turnover markers and DXA and QCT in an elderly Chinese male population[J].Ann Palliat Med,2021,10(6):6351-6358.
[59]Xu XM,Li N,Li K,et al.Discordance in diagnosis of osteoporosis by quantitative computed tomography and dualenergy X-ray absorptiometry in Chinese elderly men[J].JOrthop Translat,2018,18:59-64.
[60]中国营养学会.中国居民膳食指南(2022)[M].北京:人民卫生出版社,2022.
[61]中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2022)[J].中华骨质疏松和骨矿盐疾病杂志,2022,15(6):573-611.
[62]Shi Y,Zhan Y,Chen Y,et al.Effects of dairy products on bone mineral density in healthy postmenopausal women:a systematic review and meta-analysis of randomized controlled trials[J].Arch Osteoporos,2020,15(1):48.
[63]Bristow SM,Bolland MJ,Gamble GD,et al.Dietary calcium intake and change in bone mineral density in older adults:a systematic review of longitudinal cohort studies[J].Eur J Clin Nutr,2022,76(2):196-205.
[64]中国营养学会骨营养与健康分会,中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症患者的营养和运动管理专家共识[J].中华内分泌代谢杂志,2020,36(8):643-653.
[65]Sakhaee K,Bhuket T,Adams-Huet B,et al.Meta-analysis of calcium bioavailability:a comparison of calcium citrate with calcium carbonate[J].Am J Ther,1999,6(6):313-322.
[66]邢小平,母义明.临床路径治疗药物释义·内分泌病与代谢病分册[M].北京:中国协和医科大学出版社,2018.
[67]王琴芳,赵朝伟,杨俊卿.枸橼酸钙治疗骨质疏松症的作用特点[J].中国药业,2003,12(2):77-78.
[68]Min CY,Yoo DM,Choi HG.Associations between physical activity,sunshine duration and osteoporosis according to obesity and other lifestyle factors:a nested case-control study[J].Int J Environ Res Public Health,2021,18(9):4437.
[69]Liu H,Wang G,Wu T,et al.Efficacy and safety of eldecalcitol for osteoporosis:a meta-analysis of randomized controlled trials[J].Front Endocrinol (Lausanne),2022,13:854439.
[70]Xu Z,Fan C,Zhao X,et al.Treatment of osteoporosis with eldecalcitol,a new vitamin D analog:a comprehensive review and meta-analysis of randomized clinical trials[J].Drug Des Devel Ther,2016,10:509-517.
[71]Assantachai P,Chatthanawaree W,Thamlikitkul V,et al.Strategy to prevent falls in the Thai elderly:a controlled study integrated health research program for the Thai elderly[J].J Med Assoc Thai,2002,85(2):215-222.
[72]Minneci C,Mello AM,Mossello E,et al.Comparative study of four physical performance measures as predictors of death,incident disability,and falls in unselected older persons:the insufficienza Cardiaca negli Anziani Residenti a Dicomano Study[J].J Am Geriatr Soc,2015,63(1):136-141.
[73]Peng K,Tian M,Andersen M,et al.Incidence,risk factors and economic burden of fall-related injuries in older Chinese people:a systematic review[J].Inj Prev,2019,25(1):4-12.
[74]Gillespie LD,Robertson MC,Gillespie WJ,et al.Interventions for preventing falls in older people living in the community[J].Cochrane Database Syst Rev,2012,2012(9):CD007146.
[75]Gregson CL,Armstrong DJ,Bowden J,et al.UK clinical guideline for the prevention and treatment of osteoporosis[J].Arch Osteoporos,2022,17(1):58.
[76]Chaplin S.SIGN on managing osteoporosis and fragility fracture prevention[J].Prescriber,2021,32(2):29-32.
[77]Sinaki M.Exercise for patients with osteoporosis:management of vertebral compression fractures and trunk strengthening for fall prevention[J].PM R,2012,4(11):882-888.
[78]Wang Q,Jiang X,Shen Y,et al.Effectiveness of exercise intervention on fall-related fractures in older adults:a systematic review and meta-analysis of randomized controlled trials[J].BMC Geriatr,2020,20(1):322.
[79]Zhao R,Bu W,Chen X.The efficacy and safety of exercise for prevention of fall-related injuries in older people with different health conditions,and differing intervention protocols:a meta-analysis of randomized controlled trials[J].BMC Geriatr,2019,19(1):341.
[80]N?rgaard JE,Jorgensen MG,Ryg J,et al.Effects of gait adaptability training on falls and fall-related fractures in older adults:a systematic review and meta-analysis[J].Age Ageing,2021,50(6):1914-1924.
[81]El-Khoury F,Cassou B,Charles MA,et al.The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults:systematic review and meta-analysis of randomised controlled trials[J].BMJ,2013,347:f6234.
[82]Ong MF,Soh KL,Saimon R,et al.Fall prevention education to reduce fall risk among communitydwelling older persons:a systematic review[J].J Nurs Manag,2021,29(8):2674-2688.
[83]Scott V,Votova K,Scanlan A,et al.Multifactorial and functional mobility assessment tools for fall risk among older adults in community,home-support,long-term and acute care settings[J].Age Ageing,2007,36(2):130-139.
[84]Lachance CC,Jurkowski MP,Dymarz AC,et al.Compliant flooring to prevent fall-related injuries in older adults:a scoping review of biomechanical efficacy,clinical effectiveness,cost-effectiveness,and workplace safety[J].PLo SOne,2017,12(2):e0171652.
[85]Dautzenberg L,Beglinger S,Tsokani S,et al.Interventions for preventing falls and fallrelated fractures in communitydwelling older adults:a systematic review and network meta-analysis[J].J Am Geriatr Soc,2021,69(10):2973-2984.
[86]Hart LA,Phelan EA,Yi JY,et al.Use of fall risk-increasing drugs around a fall-related injury in older adults:a systematic review[J].J Am Geriatr Soc,2020,68(6):1334-1343.
[87]Kohrt WM,Bloomfield SA,Little KD,et al.Physical activity and bone health[J].Med Sci Sports Exerc,2004,36(11):1985-1996.
[88]Kistler-Fischbacher M,Weeks BK,Beck BR.The effect of exercise intensity on bone in postmenopausal women (part2):a meta-analysis[J].Bone,2021,143:115697.
[89]Zhao R,Zhang M,Zhang Q.The effectiveness of combined exercise interventions for preventing postmenopausal bone loss:a systematic review and meta-analysis[J].J Orthop Sports Phys Ther,2017,47(4):241-251.
[90]Babatunde OO,Bourton AL,Hind,et al.Exercise interventions for preventing and treating low bone mass in the forearm:a systematic review and meta-analysis[J].Arch Phys Med Rehabil,2020,101(3):487-511.
[91]Zhao R,Bu W,Chen X.The efficacy and safety of exercise for prevention of fall-related injuries in older people with different health conditions,and differing intervention protocols:a meta-analysis of randomized controlled trials[J].BMC Geriatr,2019,19(1):341.
[92]Pinheiro MB,Oliveira J,Bauman A,et al.Evidence on physical activity and osteoporosis prevention for people aged 65+years:a systematic review to inform the WHOguidelines on physical activity and sedentary behaviour[J].Int J Behav Nutr Phys Act,2020,17(1):150.
[93]Ponzano M,Rodrigues IB,Hosseini Z,et al.Progressive resistance training for improving health-related outcomes in people at risk of fracture:a systematic review and metaanalysis of randomized controlled trials[J].Phys Ther,2021,101(2):pzaa221.
[94]Kemmler W,Shojaa M,Kohl M,et al.Effects of different types of exercise on bone mineral density in postmenopausal women:a systematic review and meta-analysis[J].Calcif Tissue Int,2020,107(5):409-439.
[95]Piercy KL,Troiano RP,Ballard RM,et al.The physical activity guidelines for Americans[J].JAMA,2018,320(19):2020-2028.
[96]Benedetti MG,Furlini G,Zati A,et al.The effectiveness of physical exercise on bone density in osteoporotic patients[J].Biomed Res Int,2018,2018:4840531.
[97]Castellano D,Sepulveda JM,García-Escobar I,et al.The role of RANK-ligand inhibition in cancer:the story of denosumab[J].Oncologist,2011,16(2):136-145.
[98]中华医学会骨质疏松和骨矿盐疾病分会.地舒单抗在骨质疏松症临床合理用药的中国专家建议[J].中华骨质疏松和骨矿盐疾病杂志,2020,13(6):499-508.
[99]Chen Y,Zhu J,Zhou Y,et al.Efficacy and safety of denosumab in osteoporosis or low bone mineral density postmenopausal women[J].Front Pharmacol,2021,12:588095.
[100]Lyu H,Jundi B,Xu C,et al.Comparison of denosumab and bisphosphonates in patients with osteoporosis:a metaanalysis of randomized controlled trials[J].J Clin Endocrinol Metab,2019,104(5):1753-1765.
[101]Wu J,Zhang Q,Yan G,et al.Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis:a meta-analysis[J].J Orthop Surg Res,2018,13(1):194.
[102]Mandema JW,Zheng J,Libanati C,et al.Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis:a doseresponse-based meta-analysis[J].J Clin Endocrinol Metab,2014,99(10):3746-3755.
[103]Li L,Gong M,Bao D,et al.Denosumab and romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis:a reanalysis of the meta-analysis[J].Bone,2020,134:115270.
[104]Bone HG,Wagman RB,Brandi ML,et al.10 years of denosumab treatment in postmenopausal women with osteoporosis:results from the phase 3 randomised FREEDOMtrial and open-label extension[J].Lancet Diabetes Endocrinol,2017,5(7):513-523.
[105]Gopaul A,Kanagalingam T,Thain J,et al.Denosumab in chronic kidney disease:a narrative review of treatment efficacy and safety[J].Arch Osteoporos,2021,16(1):116.
[106]Chen CH,Lo WC,Hu PJ,et al.Efficacy of osteoporosis medications for patients with chronic kidney disease:an updated systematic review and network meta-analysis[J].Front Pharmacol,2022,13:822178.
[107]Cummings SR,Ferrari S,Eastell R,et al.Vertebral fractures after discontinuation of denosumab:a post hoc analysis of the randomized placebocontrolled FREEDOM trial and its extension[J].J Bone Miner Res,2018,33(2):190-198.
[108]Tsourdi E,Langdahl B,Cohen-Solal M,et al.Discontinuation of Denosumab therapy for osteoporosis:a systematic review and position statement by ECTS[J].Bone,2017,105:11-17.
[109]Wan Y,Zeng F,Tan H,et al.Cost-effectiveness analyses of denosumab for osteoporosis:a systematic review[J].Osteoporos Int,2022,33(5):979-1015.
[110]Mc Clung MR,Grauer A,Boonen S,et al.Romosozumab in postmenopausal women with low bone mineral density[J].N Engl J Med,2014,370(5):412-420.
[111]李宁,李新萍,杨明辉,等.老年髋部骨折的骨质疏松症诊疗专家共识[J].中华骨与关节外科杂志,2021,14(8):657-663.
[112]Eastell R,Rosen CJ,Black DM,et al.Pharmacological management of osteoporosis in postmenopausal women:an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab,2019,104(5):1595-1622.
[113]Camacho PM,Petak SM,Binkley N,et al.American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update[J].Endocr Pract,2020,26(Suppl 1):1-46.
[114]Kanis JA,Harvey NC,Mc Closkey E,et al.Algorithm for the management of patients at low,high and very high risk of osteoporotic fractures[J].Osteoporos Int,2020,31(1):1-12.
[115]Singh S,Dutta S,Khasbage S,et al.A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis[J].Osteoporos Int,2022,33(1):1-12.
[116]Shen J,Ke Z,Dong S,et al.Pharmacological therapies for osteoporosis:a Bayesian network meta-analysis[J].Med Sci Monit,2022,28:e935491.
[117]Cosman F,Crittenden DB,Adachi JD,et al.Romosozumab treatment in postmenopausal women with osteoporosis[J].N Engl J Med,2016,375(16):1532-1543.
[118]Saag KG,Petersen J,Brandi ML,et al.Romosozumab or alendronate for fracture prevention in women with osteoporosis[J].N Engl J Med,2017,377(15):1417-1427.
[119]Lv F,Cai X,Yang W,et al.Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis:systematic review and meta-analysis[J].Bone,2020,130:115-121.
[120]Body JJ,Bergmann P,Boonen S,et al.Non-pharmacological management of osteoporosis:a consensus of the Belgian Bone Club[J].Osteoporos Int,2011,22(11):2769-2788.
[121]Rondanelli M,Faliva MA,Barrile GC,et al.Nutrition,physical activity,and diet
基本信息:
DOI：
中图分类号:R580
引用信息:
[1]《中国老年骨质疏松症诊疗指南（2023）》工作组 ,中国老年学和老年医学学会骨质疏松分会 ,中国医疗保健国际交流促进会骨质疏松病学分会 等.中国老年骨质疏松症诊疗指南（2023）[J],2023,16(10):865-885.
基金信息:
国家重点研发计划（2020YFC2008900）